Business Support · Founded 2000 · www.mediassist.in · BSE 544088 · NSE MEDIASSIST · ISIN INE456Z01021
No Notes Added Yet
Business
Medi Assist Healthcare Services Ltd. is India's largest Third-Party Administrator (TPA) in the health insurance industry. The company acts as an intermediary between health insurance policyholders and insurance companies. Its core business model involves processing and managing health insurance claims on behalf of insurance companies. This includes cashless claims processing at network hospitals, reimbursement claims processing, call center support, pre-authorization services, and wellness programs. Medi Assist makes money by charging fees to insurance companies for these TPA services, typically based on the number of lives managed or the volume of claims processed.
Revenue Mix
Medi Assist's revenue primarily comes from providing Third-Party Administration (TPA) services.
TPA Services: This is the largest segment, encompassing claims processing (cashless and reimbursement), network management (hospitals, clinics), call center support, and grievance redressal for policyholders.
Value-Added Services: The company also offers complementary services such as corporate wellness programs, online doctor consultations, tele-consultations, health risk assessments, and pharmacy benefits management to its corporate clients. While TPA services form the dominant revenue stream, these value-added services contribute to a smaller but growing portion of overall revenue and help in client stickiness.
Industry
Medi Assist operates in the Indian health insurance TPA industry, which is regulated by the IRDAI (Insurance Regulatory and Development Authority of India). The industry is characterized by a need for extensive hospital networks, robust technology for claims processing, and compliance with regulatory guidelines. Medi Assist is a market leader, positioning itself as one of India's largest and most experienced TPAs based on the number of lives managed, network hospital presence, and market share. It serves a wide client base including public and private sector insurers, corporate groups, and retail policyholders. Its key peers include other IRDAI-licensed TPAs like Vidal Health, Health India, and Family Health Plan.
MOAT
Scale & Network: As a large TPA, Medi Assist possesses an extensive network of hospitals and healthcare providers across India, which is critical for efficient cashless claims processing. Building and maintaining such a vast, pan-India network is time-consuming and capital-intensive for new entrants.
Operational Efficiency & Technology: Significant investments in proprietary technology platforms and automation for claims processing, data analytics, and fraud detection lead to operational efficiencies and better service delivery.
Data & Insights: Managing a large volume of claims provides valuable data, enabling better underwriting support for insurers and insights into healthcare utilization patterns.
Switching Costs (for Insurers): For insurance companies, switching TPAs involves significant integration efforts with new systems, data migration, and potential disruption to policyholder services, creating a degree of stickiness.
Regulatory Experience: Established compliance frameworks and long-standing relationships with regulatory bodies.
Growth Drivers
Increasing Health Insurance Penetration: India's health insurance penetration remains relatively low, offering significant headroom for growth as awareness and disposable incomes rise.
Rising Healthcare Costs: Escalating medical inflation and prevalence of lifestyle diseases drive demand for comprehensive health insurance coverage.
Government Initiatives: Policies promoting health insurance and wellness, though not directly TPA-focused, contribute to the overall expansion of the healthcare ecosystem.
Digitization & Technology Adoption: Growing use of digital platforms for policy management, claims submission, and telemedicine streamlines TPA operations and enhances customer experience.
Expansion of Corporate & Retail Segments: Continued growth in both employer-sponsored group health insurance and individual/family health policies.
Untapped Potential in Tier 2/3 Cities: Expansion into smaller cities and towns offers new markets for health insurance and TPA services.
Risks
Regulatory Changes: Any adverse changes in IRDAI regulations regarding TPA fees, scope of services, or compliance requirements could impact profitability and business model.
Competition & Pricing Pressure: Intense competition from existing TPAs, potential new entrants, or even insurers insourcing TPA functions can lead to pressure on service fees and margins.
Dependence on Insurers: Revenue is highly dependent on relationships with insurance companies. Loss of major insurer contracts could significantly impact business.
Technological Obsolescence & Cybersecurity: Failure to keep pace with technological advancements or cybersecurity breaches could lead to reputational damage and operational disruption.
Economic Downturn: A significant economic slowdown could affect health insurance uptake, particularly in the retail segment, and impact corporate spending on employee benefits.
Operational Efficiency: Inability to manage claims efficiently, control costs, or detect fraud could lead to financial losses or penalties.
Management & Ownership
Medi Assist was founded by Dr. Vikram Jit Singh Chhatwal and Ms. Satvinder Kaur, who continue to be key promoters and hold significant leadership positions within the company. Dr. Chhatwal serves as the Chairman and CEO, bringing extensive experience in the healthcare and insurance administration domain. The management team generally consists of professionals with a background in healthcare, insurance, and technology. Post-IPO, the ownership structure includes the promoter group, institutional investors (Foreign Institutional Investors, Domestic Institutional Investors), and public shareholders. The company has a board of directors with independent members to ensure governance standards.
Outlook
Medi Assist Healthcare Services is well-positioned to capitalize on India's underpenetrated and growing health insurance market. The long-term outlook is positive due to increasing health awareness, rising healthcare costs, and the ongoing formalization and digitalization of healthcare services. Its market leadership, extensive network, and technological capabilities provide a strong foundation for continued growth.
However, the company operates in a regulated and competitive environment. Key challenges include potential pricing pressures from insurers, evolving regulatory landscape, and the need for continuous investment in technology and network expansion. While the core TPA business remains robust, its ability to innovate and successfully expand into value-added services like wellness and preventive care will be crucial for diversifying revenue streams and enhancing profitability in the future.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 166 | 167 | 168 | 181 | 186 | 189 | 191 | 233 | 240 | 242 |
| Other Income | 4 | 4 | 5 | 6 | 4 | 8 | 7 | 2 | 8 | 1 |
| Total Income | 170 | 171 | 173 | 187 | 190 | 197 | 198 | 235 | 247 | 243 |
| Total Expenditure | 132 | 130 | 132 | 142 | 146 | 148 | 149 | 193 | 195 | 194 |
| Operating Profit | 38 | 41 | 40 | 45 | 44 | 49 | 49 | 42 | 52 | 50 |
| Interest | 1 | 1 | 2 | 2 | 2 | 4 | 5 | 8 | 8 | 1 |
| Depreciation | 11 | 12 | 14 | 14 | 14 | 14 | 14 | 21 | 21 | 21 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14 | 0 |
| Profit Before Tax | 26 | 28 | 25 | 29 | 27 | 30 | 31 | 13 | 8 | 28 |
| Provision for Tax | 4 | 3 | 6 | 9 | -3 | 8 | 8 | 5 | 4 | -27 |
| Profit After Tax | 21 | 26 | 19 | 21 | 30 | 22 | 23 | 8 | 4 | 54 |
| Adjustments | -1 | -1 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -1 |
| Profit After Adjustments | 21 | 25 | 19 | 21 | 30 | 21 | 22 | 8 | 4 | 53 |
| Adjusted Earnings Per Share | 3 | 3.6 | 2.7 | 3 | 4.2 | 3 | 3.2 | 1.1 | 0.6 | 7.2 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 341 | 406 | 319 | 323 | 394 | 505 | 635 | 723 | 906 |
| Other Income | 11 | 4 | 12 | 25 | 28 | 14 | 26 | 27 | 18 |
| Total Income | 352 | 410 | 330 | 348 | 422 | 519 | 661 | 751 | 923 |
| Total Expenditure | 270 | 331 | 241 | 249 | 312 | 386 | 509 | 573 | 731 |
| Operating Profit | 82 | 80 | 90 | 98 | 109 | 133 | 152 | 178 | 193 |
| Interest | 4 | 4 | 4 | 6 | 3 | 3 | 3 | 10 | 22 |
| Depreciation | 19 | 25 | 26 | 32 | 28 | 27 | 43 | 56 | 77 |
| Exceptional Income / Expenses | 0 | -11 | 0 | 0 | 3 | 0 | -21 | 0 | -14 |
| Profit Before Tax | 59 | 39 | 59 | 61 | 81 | 104 | 84 | 112 | 80 |
| Provision for Tax | 19 | 13 | 21 | 23 | 17 | 28 | 13 | 20 | -10 |
| Profit After Tax | 40 | 26 | 38 | 38 | 63 | 75 | 71 | 92 | 89 |
| Adjustments | 0 | 0 | -8 | -11 | 1 | -1 | -4 | -1 | -1 |
| Profit After Adjustments | 40 | 26 | 31 | 27 | 64 | 74 | 67 | 91 | 87 |
| Adjusted Earnings Per Share | 6.2 | 3.9 | 4.6 | 3.9 | 9.3 | 10.8 | 9.5 | 12.9 | 12.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 14% | 22% | 18% | 0% |
| Operating Profit CAGR | 17% | 18% | 15% | 0% |
| PAT CAGR | 30% | 13% | 19% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -28% | NA% | NA% | NA% |
| ROE Average | 18% | 19% | 19% | 18% |
| ROCE Average | 21% | 24% | 24% | 23% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 204 | 218 | 211 | 290 | 337 | 377 | 472 | 541 |
| Minority's Interest | 3 | 2 | 2 | 2 | 2 | 7 | 10 | 11 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
| Other Non-Current Liabilities | 43 | 41 | 39 | 113 | 19 | 34 | 192 | 257 |
| Total Current Liabilities | 229 | 255 | 302 | 219 | 234 | 279 | 475 | 686 |
| Total Liabilities | 480 | 516 | 555 | 624 | 593 | 697 | 1148 | 1508 |
| Fixed Assets | 132 | 142 | 138 | 119 | 99 | 171 | 246 | 306 |
| Other Non-Current Assets | 81 | 91 | 110 | 133 | 69 | 83 | 268 | 269 |
| Total Current Assets | 267 | 283 | 308 | 370 | 425 | 442 | 633 | 933 |
| Total Assets | 480 | 516 | 555 | 624 | 593 | 697 | 1148 | 1508 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 15 | 6 | 11 | -5 | 63 | 15 | 54 | 51 |
| Cash Flow from Operating Activities | 40 | 35 | 17 | 139 | 64 | 81 | 66 | 138 |
| Cash Flow from Investing Activities | -42 | -21 | -21 | -61 | -83 | -10 | -55 | -218 |
| Cash Flow from Financing Activities | -7 | -10 | -12 | -10 | -30 | -32 | -15 | 112 |
| Net Cash Inflow / Outflow | -9 | 4 | -16 | 69 | -49 | 39 | -3 | 32 |
| Closing Cash & Cash Equivalent | 6 | 10 | -5 | 63 | 15 | 54 | 51 | 83 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.24 | 3.93 | 4.58 | 3.89 | 9.33 | 10.76 | 9.53 | 12.89 |
| CEPS(Rs) | 0 | 0 | 0 | 0 | 13.34 | 14.82 | 16.29 | 20.9 |
| DPS(Rs) | 0 | 0 | 0 | 2.5 | 1.89 | 1.89 | 4 | 0 |
| Book NAV/Share(Rs) | 30.46 | 31.85 | 30.87 | 41.56 | 47.81 | 53.08 | 65.98 | 75.68 |
| Core EBITDA Margin(%) | 20.82 | 18.55 | 24.37 | 22.76 | 20.66 | 23.64 | 19.73 | 20.81 |
| EBIT Margin(%) | 18.38 | 10.72 | 19.83 | 20.69 | 21.24 | 21.11 | 13.79 | 16.88 |
| Pre Tax Margin(%) | 17.34 | 9.67 | 18.66 | 18.91 | 20.49 | 20.52 | 13.3 | 15.45 |
| PAT Margin (%) | 11.85 | 6.45 | 11.98 | 11.78 | 16.12 | 14.91 | 11.23 | 12.66 |
| Cash Profit Margin (%) | 17.39 | 12.56 | 20.24 | 21.54 | 23.33 | 20.22 | 18.02 | 20.38 |
| ROA(%) | 8.43 | 5.26 | 7.12 | 6.44 | 10.43 | 11.68 | 7.73 | 6.9 |
| ROE(%) | 20.48 | 12.78 | 18.25 | 15.49 | 20.67 | 21.68 | 17.21 | 18.38 |
| ROCE(%) | 24.45 | 16.52 | 22.82 | 23.27 | 26.66 | 29.87 | 20.64 | 20.99 |
| Receivable days | 104.41 | 84.43 | 134 | 149.74 | 111.15 | 88.89 | 87.92 | 100.92 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 53.01 | 35.27 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 7.66 | 6.01 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0.79 | 0 |
| EV/Net Sales(x) | 0.12 | 0.1 | 0.1 | -0.36 | -0.07 | -0.35 | 5.33 | 4.38 |
| EV/Core EBITDA(x) | 0.5 | 0.49 | 0.37 | -1.17 | -0.26 | -1.33 | 22.32 | 17.82 |
| Net Sales Growth(%) | 0 | 18.94 | -21.54 | 1.3 | 22.02 | 28.22 | 25.7 | 13.96 |
| EBIT Growth(%) | 0 | -30.63 | 45.16 | 5.67 | 25.27 | 27.45 | -17.87 | 39.44 |
| PAT Growth(%) | 0 | -35.24 | 45.69 | -0.39 | 66.99 | 18.66 | -5.33 | 28.48 |
| EPS Growth(%) | 0 | -37.04 | 16.59 | -14.97 | 139.47 | 15.32 | -11.35 | 35.16 |
| Debt/Equity(x) | 0.27 | 0.25 | 0.35 | 0 | 0 | 0 | 0 | 0.28 |
| Current Ratio(x) | 1.17 | 1.11 | 1.02 | 1.7 | 1.81 | 1.59 | 1.33 | 1.36 |
| Quick Ratio(x) | 1.17 | 1.11 | 1.02 | 1.7 | 1.81 | 1.59 | 1.33 | 1.36 |
| Interest Cover(x) | 17.69 | 10.17 | 16.93 | 11.66 | 28.35 | 35.66 | 27.65 | 11.85 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 38.91 | 38.85 | 20.6 | 20.56 | 20.56 | 20.55 | 4.87 | 4.62 | 4.61 |
| FII | 9.67 | 9.76 | 16.25 | 14.04 | 13.26 | 13.89 | 23 | 25.28 | 24.32 |
| DII | 30.61 | 29.18 | 41.32 | 42.71 | 42.9 | 42.28 | 48.89 | 49.89 | 49.18 |
| Public | 20.81 | 22.21 | 21.83 | 22.69 | 23.28 | 23.28 | 23.25 | 20.21 | 21.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.73 | 2.73 | 1.45 | 1.45 | 1.45 | 1.45 | 0.34 | 0.34 | 0.34 |
| FII | 0.68 | 0.69 | 1.14 | 0.99 | 0.94 | 0.98 | 1.62 | 1.88 | 1.81 |
| DII | 2.15 | 2.05 | 2.91 | 3.01 | 3.03 | 2.98 | 3.45 | 3.71 | 3.67 |
| Public | 1.46 | 1.56 | 1.54 | 1.6 | 1.64 | 1.64 | 1.64 | 1.5 | 1.63 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7.02 | 7.03 | 7.04 | 7.05 | 7.05 | 7.05 | 7.06 | 7.45 | 7.46 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +14% | +22% | +18% | — |
| Operating Profit CAGR | +17% | +18% | +15% | — |
| PAT CAGR | +30% | +13% | +19% | — |
| Share Price CAGR | -28% | — | — | — |
| ROE Average | +18% | +19% | +19% | +18% |
| ROCE Average | +21% | +24% | +24% | +23% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 38.91 | 38.85 | 20.6 | 20.56 | 20.56 | 20.55 | 4.87 | 4.62 | 4.61 |
| FII | 9.67 | 9.76 | 16.25 | 14.04 | 13.26 | 13.89 | 23 | 25.28 | 24.32 |
| DII | 30.61 | 29.18 | 41.32 | 42.71 | 42.9 | 42.28 | 48.89 | 49.89 | 49.18 |
| Public | 61.09 | 61.15 | 79.4 | 79.44 | 79.44 | 79.45 | 95.13 | 95.38 | 95.39 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.73 | 2.73 | 1.45 | 1.45 | 1.45 | 1.45 | 0.34 | 0.34 | 0.34 |
| FII | 0.68 | 0.69 | 1.14 | 0.99 | 0.94 | 0.98 | 1.62 | 1.88 | 1.81 |
| DII | 2.15 | 2.05 | 2.91 | 3.01 | 3.03 | 2.98 | 3.45 | 3.71 | 3.67 |
| Public | 4.29 | 4.3 | 5.59 | 5.6 | 5.6 | 5.6 | 6.72 | 7.1 | 7.12 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7.02 | 7.03 | 7.04 | 7.05 | 7.05 | 7.05 | 7.06 | 7.45 | 7.46 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.